RT Journal Article
SR Electronic
T1 Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP ERJ-02182-2014
DO 10.1183/09031936.00218214
A1 Caroline Abdulmalak
A1 Jonathan Cottenet
A1 Guillaume Beltramo
A1 Marjolaine Georges
A1 Philippe Camus
A1 Philippe Bonniaud
A1 Catherine Quantin
YR 2015
UL http://erj.ersjournals.com/content/early/2015/05/28/09031936.00218214.abstract
AB Haemoptysis is a serious symptom with various aetiologies. Our aim was to define the aetiologies, outcomes and associations with lung cancer in the entire population of a high-income country.This retrospective multicentre study was based on the French nationwide hospital medical information database collected over 5 years (2008–2012).We analysed haemoptysis incidence, aetiologies, geographical and seasonal distribution and mortality. We studied recurrence, association with lung cancer and mortality in a 3-year follow-up analysis.Each year, ∼15 000 adult patients (mean age 62 years, male/female ratio 2/1) were admitted for haemoptysis or had haemoptysis as a complication of their hospital stay, representing 0.2% of all hospitalised patients. Haemoptysis was cryptogenic in 50% of cases. The main aetiologies were respiratory infections (22%), lung cancer (17.4%), bronchiectasis (6.8%), pulmonary oedema (4.2%), anticoagulants (3.5%), tuberculosis (2.7%), pulmonary embolism (2.6%) and aspergillosis (1.1%). Among incident cases, the 3-year recurrence rate was 16.3%. Of the initial cryptogenic haemoptysis patients, 4% were diagnosed with lung cancer within 3 years. Mortality rates during the first stay and at 1 and 3 years were 9.2%, 21.6% and 27%, respectively.This is the first epidemiological study analysing haemoptysis and its outcomes in an entire population. Haemoptysis is a life-threatening symptom unveiling potentially life-threatening underlying conditions.Haemoptysis is ominous: there is often no clear aetiology and 4% of patients develop lung cancer during follow-up http://ow.ly/KqJDG